期刊文献+

2018年口腔专科医院国家基本药物应用分析与管理模式探索 被引量:6

Application Analysis and Management Mode Exploration of National Essential Drugs in Stomatology Hospital in 2018
暂未订购
导出
摘要 目的:了解口腔专科医院国家基本药物使用情况,为促进临床合理使用基本药物提供参考;探索优化口腔专科医院国家基本药物的管理模式,为有效降低患者药费负担提供参考。方法:调查2018年四川大学华西口腔医院(以下简称"我院")HIS系统中国家基本药物的使用数据,按照药物种类、销售金额等进行统计分析,并结合分析结果提出相应的管理措施。结果:2018年,我院194种药品中,国家基本药物74种(以化学药和生物制品为主,共70种),占我院药品总品种数的38.14%;我院药品总销售金额为2123.07万元,其中国家基本药物销售金额为663.85万元(占31.27%);国家基本药物中,销售金额排序居前3位的药品为吸入用七氟烷、哌拉西林他唑巴坦注射液和头孢呋辛注射液,三者销售金额合计占比达50.11%。创新国家基本药物管理模式:成立基本药物管理小组,采取信息化建设、量化考核指标、专项处方点评和加强培训等措施。结论:我院国家基本药物的使用情况符合口腔专科用药特点。应不断探索国家基本药物管理模式,促进药物的合理应用,有效降低患者用药负担。 OBJECTIVE:To investigate the application of national essential drugs in stomatology hospital,so as to provide reference for the rational application of national essential drugs in clinic.To explore and optimize the management mode of national essential drugs in stomatology hospital,so as to provide reference for effectively reducing the burden of patients’drug costs.METHODS:The application data of national essential drugs in HIS system of Hospital of Stomatology,Sichuan Universit(hereinafter referred to as"our hospital")in 2018 was investigated,statistical analysis was conducted according to drug categories and sales amount,and corresponding management measures based on the analysis results was formulated.RESULTS:In 2018,among 194 kinds of drugs in our hospital,74 categories were national essential drugs(mainly for chemical drugs and biological products,totally 70 categories),38.14%of the total drugs in our hospital.The consumption sum of drugs in our hospital were 21.2307 million yuan,of which national essential drugs were 6.6385 million yuan(accounted for 31.27%).The top 3 drugs ranked by consumption sum were respectively inhalation of sevoflurane,piperacillin tazobactam injection and cefuroxime injection,the proportion of consumption sum of the three drugs was 50.11%.In order to innovate the national essential drugs management model,the essential drugs management team should be established to take measures such as informatization construction,quantitative assessment indicators,special prescription review and enhanced training.CONCLUSIONS:The application of national essential drugs in our hospital conforms to the characteristics of oral specialty drugs.It is necessary to explore the management mode of national essential drugs,promote the rational application of drugs,and effectively reduce the burden of patients.
作者 王建莉 李佳 赵科 邹紫鑫 WANG Jianli;LI Jia;ZHAO Ke;ZOU Zixin(Dept.of Pharmacy,Hospital of Stomatology,Sichuan University,Sichuan Chengdu 610041,China;National Drug Clinical Trial Institution,Hospital of stomatology,Sichuan University,Sichuan Chengdu 610041,China)
出处 《中国医院用药评价与分析》 2020年第1期107-109,113,共4页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 口腔医院 国家基本药物 合理用药 管理模式 Stomatology hospital National essential drugs Rational application of drugs Management mode
  • 相关文献

参考文献10

二级参考文献127

  • 1王教玉,张起辉,邓旭明,王大成,韩文瑜.没食子的药理研究进展[J].时珍国医国药,2007,18(10):2570-2572. 被引量:33
  • 2Giedraitiene A, Vitkauskiene A, Naginiene R, et al. Antibiotic resistance mechanisms of clinically important bacteria[J]. Medicina (Kaunas), 2011, 47(3): 137-146.
  • 3Lee J H, Bae I K, Lee S H. New definitions of extended- spectrum 13-1actamase conferring worldwide emergingantibiotic resistance[J]. Med Res Rev, 2012, 32(1): 216-232.
  • 4Bush K, Fisher J F. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria[J]. Annu Rev Microbiol, 2011, 65: 455-478.
  • 5Bebrone C, Lassaux P, Vercheval L, et al. Current challenges in antimicrobial chemotherapy: focus on β-1actamase inhibition[J]. Drugs, 2010,70(6): 651-679.
  • 6Drawz S M, Bonomo R A.Three decades of beta-lactamase inhibitors[J]. Clin Microbiol Rev, 2010, 23(1): 160-201.
  • 7Paukner S, Hesse L, Prezelj A, et al. In vitro activity of LK- 157, a novel tricyclic carbapenem as broad-spectrum {beta}- lactamase inhibitor[J]. Antimicrob Agents Chemother, 2009, 53(2): 505-511.
  • 8Papp-Wallace K M, Bethel C R, Gootz T D, et al. Inactivation of a class A and a class C β-1actamase by 6β-(hydroxymethyl)penicillanic acid sulfone[J]. Biochem Pharmacol, 2012, 83(4): 462-471.
  • 9Stachyra T, P6chereau M C, Bruneau J M, et al. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor[J]. Antimicrob Agents Chemother, 2010, 54(12): 5132-5138.
  • 10Lagac6-Wiens P R, Tailor F, Simner P, et al. Activityof NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases[J]. Antimicrob Agents Chemother, 2011, 55(5): 2434-2437.

共引文献200

同被引文献67

引证文献6

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部